IL164440A0 - New pharmaceutical composition containing fibanserin polymorph a - Google Patents

New pharmaceutical composition containing fibanserin polymorph a

Info

Publication number
IL164440A0
IL164440A0 IL16444004A IL16444004A IL164440A0 IL 164440 A0 IL164440 A0 IL 164440A0 IL 16444004 A IL16444004 A IL 16444004A IL 16444004 A IL16444004 A IL 16444004A IL 164440 A0 IL164440 A0 IL 164440A0
Authority
IL
Israel
Prior art keywords
polymorph
fibanserin
pharmaceutical composition
composition containing
new pharmaceutical
Prior art date
Application number
IL16444004A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL164440A0 publication Critical patent/IL164440A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL16444004A 2002-05-22 2004-10-05 New pharmaceutical composition containing fibanserin polymorph a IL164440A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02011224 2002-05-22
PCT/EP2003/005226 WO2003097058A1 (en) 2002-05-22 2003-05-19 New pharmaceutical compositions containing flibanserin polymorph a

Publications (1)

Publication Number Publication Date
IL164440A0 true IL164440A0 (en) 2005-12-18

Family

ID=29433081

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16444004A IL164440A0 (en) 2002-05-22 2004-10-05 New pharmaceutical composition containing fibanserin polymorph a

Country Status (25)

Country Link
EP (1) EP1511489B1 (enExample)
JP (1) JP3919788B2 (enExample)
KR (1) KR101054237B1 (enExample)
CN (3) CN102240289A (enExample)
AT (1) ATE499939T1 (enExample)
BR (1) BRPI0311189B8 (enExample)
CA (1) CA2483597C (enExample)
CY (1) CY1111470T1 (enExample)
DE (1) DE60336225D1 (enExample)
DK (1) DK1511489T3 (enExample)
EA (1) EA007185B1 (enExample)
EC (1) ECSP045493A (enExample)
ES (1) ES2361994T3 (enExample)
HR (1) HRP20041092B1 (enExample)
IL (1) IL164440A0 (enExample)
ME (1) MEP55308A (enExample)
MX (1) MXPA04011487A (enExample)
NO (1) NO329414B1 (enExample)
NZ (1) NZ537253A (enExample)
PL (1) PL211062B1 (enExample)
RS (1) RS51718B (enExample)
SI (1) SI1511489T1 (enExample)
UA (1) UA80135C2 (enExample)
WO (1) WO2003097058A1 (enExample)
ZA (1) ZA200408151B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
EP1912650B8 (en) 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
JP2009541443A (ja) * 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CN104721168A (zh) 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放系统及其制造方法
WO2008074795A1 (en) 2006-12-20 2008-06-26 Boehringer Ingelheim International Gmbh Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017128932A1 (zh) * 2016-01-31 2017-08-03 孟晓明 氟班色林的新晶型及其制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
AU2002331361B2 (en) * 2001-08-02 2008-06-05 Sprout Pharmaceuticals, Inc. Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung

Also Published As

Publication number Publication date
CA2483597C (en) 2010-02-09
CN1655789A (zh) 2005-08-17
MEP55308A (en) 2011-05-10
PL211062B1 (pl) 2012-04-30
BR0311189A (pt) 2005-02-22
DK1511489T3 (da) 2011-05-02
CN101002780A (zh) 2007-07-25
ES2361994T3 (es) 2011-06-27
WO2003097058A1 (en) 2003-11-27
KR20040111668A (ko) 2004-12-31
MXPA04011487A (es) 2005-02-14
NZ537253A (en) 2007-09-28
UA80135C2 (en) 2007-08-27
BRPI0311189B8 (pt) 2021-05-25
CN102240289A (zh) 2011-11-16
HRP20041092B1 (hr) 2013-05-31
JP2005530787A (ja) 2005-10-13
RS98704A (sr) 2006-12-15
ZA200408151B (en) 2006-06-28
KR101054237B1 (ko) 2011-08-08
JP3919788B2 (ja) 2007-05-30
NO329414B1 (no) 2010-10-18
NO20044547L (no) 2004-12-17
HRP20041092A2 (en) 2005-06-30
SI1511489T1 (sl) 2011-06-30
EP1511489A1 (en) 2005-03-09
EA007185B1 (ru) 2006-08-25
CA2483597A1 (en) 2003-11-27
EP1511489B1 (en) 2011-03-02
DE60336225D1 (de) 2011-04-14
PL372457A1 (en) 2005-07-25
BRPI0311189B1 (pt) 2019-04-09
AU2003240672A1 (en) 2003-12-02
EA200401515A1 (ru) 2005-06-30
ECSP045493A (es) 2005-03-10
RS51718B (sr) 2011-10-31
CY1111470T1 (el) 2015-08-05
ATE499939T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UA96449C2 (en) Stable laquinimod preparations
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
PL370292A1 (en) Formulations for oral administration of active compounds
IL190218A0 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
AP1787A (en) Novel perindopril salt and pharmaceutical compositions containing same.
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
ZA200500203B (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
AU2003231920A8 (en) Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
MY142076A (en) Emulsifying systems containing azetidine derivatives
NO20064808L (no) Orale matrixformuleringer med licarbazepin
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
AU2003284786A8 (en) Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
SG144141A1 (en) Semi-solid systems containing azetidine derivatives
TW200633717A (en) Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
ZA200501010B (en) BenzoÄBÜchromeno-naphthyridin-7-one and pyranoÄ2'3':7,8ÜquinoÄ2,3-BÜquinoxalin-7-one compounds, process for their preparation and pharmaceutical compositions containing them.